Ten Years Real-World Experience With Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction [0.03%]
心力衰竭患者使用沙库巴曲缬沙坦的10年真实世界经验
Gianluigi Savarese,Christian Basile,Alexandre Mebazaa et al.
Gianluigi Savarese et al.
Aims: To provide a comprehensive overview of real-world evidence (RWE) regarding the implementation, clinical effectiveness, and safety of Sacubitril/valsartan (Sac/Val) in patients with Heart Failure (HF) with reduced ej...
Quantifying skeletal muscle energy metabolism during exercise in heart failure with preserved ejection fraction using in vivo 31P magnetic resonance spectroscopy [0.03%]
使用体内31P磁共振波谱法量化保留射血分数心力衰竭患者运动时骨骼肌能量代谢状况
Jerremy Weerts,Suzanne N Voorrips,Jeroen A L Jeneson et al.
Jerremy Weerts et al.
Background and aims: Patients with heart failure and preserved ejection fraction (HFpEF) experience significant exercise intolerance, yet its underlying mechanisms remain poorly defined and are multifactorial. Iron defici...
Multicenter Study
ESC heart failure. 2026 Mar 3;13(2):xvaf035. DOI:10.1093/eschf/xvaf035 2026
Effect of heart rate reduction with ivabradine on quality of life in advanced cancer patients [0.03%]
伊伐布雷定减慢心率对晚期癌症患者生活质量的影响
Yvonne Bewarder,Angela Zimmer,Markus Anker et al.
Yvonne Bewarder et al.
Global Burden of Heart Failure Attributable to Atrial Fibrillation and Flutter, insights from GBD 2021 [0.03%]
基于GBD 2021的全球心房颤动和心房扑动导致的心力衰竭疾病负担分析
Junpeng Xiong,Shiyang Guan,Cheng Cheng et al.
Junpeng Xiong et al.
Aims: To systematically quantify the global, regional, and national burden of heart failure (HF) attributable to atrial fibrillation/flutter (AF/AFL) from 1990 to 2021, and project trends to 2040. ...
Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry [0.03%]
优化射血分数降低的心力衰竭患者临床试验中NT-proBNP的纳入界值：来自瑞典心力衰竭注册登记的数据
Megan Schroeder,Lars H Lund,Christoph Gerlinger et al.
Megan Schroeder et al.
Aims: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is widely used as an enrichment criterion in heart failure (HF) randomized controlled trials (RCTs), yet cut-offs vary. This study aims to provide evidence-based...
Does the Method Matter? Direct Fick Versus Thermodilution in the Haemodynamic Assessment of Pulmonary Hypertension [0.03%]
方法重要吗？肺动脉高压血流动力学评价中直接Fick法与热稀释法的比较
Léon Genecand,Athénaïs Boucly,Olivier Sitbon et al.
Léon Genecand et al.
Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors [0.03%]
激发和运动显像在心脏肌球蛋白抑制剂适用对象识别中的作用
Jonas Erzeel,Sebastiaan Dhont,Marnicq van Es et al.
Jonas Erzeel et al.
Aims: Left ventricular outflow tract obstruction (LVOTO) drives symptoms and functional limitation in obstructive hypertrophic cardiomyopathy (oHCM). Some patients may only show treatment-qualifying obstruction during exe...
Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure [0.03%]
急性心力衰竭中体质指数的性别和表型特异性预后意义
Yoonsun Won,Mi-Seung Shin,Eunji Kim et al.
Yoonsun Won et al.
Aims: This study aimed to determine whether the prognostic implications of body mass index (BMI) differ according to heart failure (HF) phenotype and sex. ...
Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity [0.03%]
GLP-1受体激动剂预防2型糖尿病和/或肥胖人群心力衰竭事件的效果分析
Keerthenan Raveendra,Tobin Joseph,Jing Kang et al.
Keerthenan Raveendra et al.
Introduction: Heart failure (HF) is a common sequela of diabetes and obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists may prevent HF events. This meta-analysis estimates absolute risk reduction (ARR) and number ...
Meta-Analysis
ESC heart failure. 2026 Mar 3;13(2):xvag091. DOI:10.1093/eschf/xvag091 2026
The Cardio-Pancreatic Axis in Heart Failure: From Conceptual Framework to Empirical Evidence [0.03%]
心力衰竭中心血管-胰腺轴的研究：从概念框架到实证证据
Olivier C Dams,Marlene A T Vijver,Robert C Verdonk et al.
Olivier C Dams et al.